Type 2 diabetes is the most common form of diabetes. It can be diagnosed at any age and increases your risk of several other health problems. Farxiga (far-see-guh) is just one of the many prescription ...

Both Farxiga (dapagliflozin) and Jardiance (empagliflozin) help manage blood sugar levels in adults and some children with type 2 diabetes. They also reduce risks associated with chronic kidney ...

Question: I paid so much for my Eliquis this year, will I have to pay that much next year too? Answer: The good news is no, seniors will not pay as much for Eliquis as well as nine other common ...

Farxiga is a prescription oral tablet used to manage type 2 diabetes or certain heart or kidney conditions. It’s a brand-name drug with the active ingredient dapagliflozin. Farxiga tablets come in ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

Farxiga (dapagliflozin) is a prescription, brand-name medication. The Food and Drug Administration (FDA) has approved Farxiga for uses in certain adults. These uses include: Farxiga comes as an oral ...

With seven posters and nine presentations on Farxiga over the weekend at the European Society of Cardiology (ESC) scientific sessions in Amsterdam, AstraZeneca made it clear that it has lots to say ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...

Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful ...